Literature DB >> 3339800

Silent ischemia on Holter monitoring predicts mortality in high-risk postinfarction patients.

S O Gottlieb1, S H Gottlieb, S C Achuff, R Baumgardner, E D Mellits, M L Weisfeldt, G Gerstenblith.   

Abstract

The relative prognostic significance of ischemic ST changes on two-lead continuous electrocardiographic (Holter) monitoring in 103 high-risk postinfarction patients was examined. Ischemic ST changes were detected in 30 patients, with a median number of five episodes per day and median total daily duration of 157 minutes. Only one third of these patients reported any angina in the hospital, and 28 of the 30 patients had silent ST changes on Holter monitoring. The remaining 73 patients had no ischemic ST changes on Holter monitoring. At one year, nine (30%) of 30 patients with ischemic ST changes were dead vs only eight (11%) of 73 patients without such changes. Multivariate Cox's hazard function analysis on 18 variables, including age, type of infarction, Lown and Killip class, ejection fraction, and medications, showed that the presence of ST changes on Holter monitoring was a significant predictive variable for one-year mortality in the overall study population and particularly in the subgroup of 59 patients who could not undergo early exercise treadmill testing. Thus, ischemic ST changes on Holter monitoring, the majority of which are silent, occur in nearly one third of high-risk postinfarction patients and are significantly associated with one-year mortality.

Entities:  

Mesh:

Year:  1988        PMID: 3339800

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  38 in total

1.  Transient myocardial ischaemia after acute myocardial infarction.

Authors:  P Currie; S Saltissi
Journal:  Br Heart J       Date:  1990-11

Review 2.  Perioperative myocardial ischaemia.

Authors:  I R Thomson
Journal:  Can J Anaesth       Date:  1989-05       Impact factor: 5.063

Review 3.  Silent myocardial ischaemia. Implications for therapy.

Authors:  N G Uren; D P Lipkin
Journal:  Drugs       Date:  1991-06       Impact factor: 9.546

4.  Myocardial ischemia, reperfusion, and infarction in chronically instrumented, intact, conscious, and unrestrained mice.

Authors:  Heidi L Lujan; Hussein Janbaih; Han-Zhong Feng; Jian-Ping Jin; Stephen E DiCarlo
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2012-04-25       Impact factor: 3.619

5.  Predicting ischaemic events in the perioperative period: in search of the perfect tool.

Authors:  J C Tardif; M Juneau
Journal:  Can J Anaesth       Date:  1996-10       Impact factor: 5.063

6.  Clinical features of potential after-effects of percutaneous coronary intervention in the treatment of silent myocardial ischemia.

Authors:  Shinichiro Doi; Makoto Suzuki; Takehiro Funamizu; Itaru Takamisawa; Tetsuya Tobaru; Hiroyuki Daida; Mitsuaki Isobe
Journal:  Heart Vessels       Date:  2019-06-06       Impact factor: 2.037

7.  Transient myocardial ischaemia after acute myocardial infarction does not induce ventricular arrhythmias.

Authors:  P Currie; S Saltissi
Journal:  Br Heart J       Date:  1993-04

8.  Prognostic significance of transient myocardial ischaemia after first acute myocardial infarction: five year follow up study.

Authors:  H Mickley; J R Nielsen; J Berning; A Junker; M Møller
Journal:  Br Heart J       Date:  1995-04

9.  The total ischemic burden European trial (TIBET): design, methodology, and management. The TIBET Study Group.

Authors: 
Journal:  Cardiovasc Drugs Ther       Date:  1992-08       Impact factor: 3.727

10.  Cardiovascular risk evaluation and prevalence of silent myocardial ischemia in subjects with asymptomatic carotid artery disease.

Authors:  Marco Matteo Ciccone; Artor Niccoli-Asabella; Pietro Scicchitano; Michele Gesualdo; Antonio Notaristefano; Domenico Chieppa; Santa Carbonara; Gabriella Ricci; Marco Sassara; Corinna Altini; Giovanni Quistelli; Mario Erminio Lepera; Stefano Favale; Giuseppe Rubini
Journal:  Vasc Health Risk Manag       Date:  2011-03-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.